The Role of Histone Methyltransferases and Long Non-coding RNAs in the Regulation of T Cell Fate Decisions

Joseph M. Gaballa, Manuel Bonfim Braga Neto, Guilherme Piovezani Ramos, Adebowale O. Bamidele, Michelle M. Gonzalez, Mary R. Sagstetter, Olga F. Sarmento and William A. Faubion Jr.*

T cell lineage decisions are critical for the development of proper immune responses to pathogens as well as important for the resolution of inflammatory responses. This differentiation process relies on a combination of intrinsic and extrinsic factors converging upon epigenetic regulation of transcriptional networks relevant to specific T cell lineages. As these biochemical modifications represent therapeutic opportunities in cancer biology and autoimmunity, implications of writers and readers of epigenetic marks to immune cell differentiation and function are highly relevant. Given the ready adoption of histone methyltransferase inhibitors in the clinic, we focus this review on the role of three histone modifying complexes: PRC-1, PRC-2, and G9A in modulating T cell fate decisions. Furthermore, we explore the role of long non-coding RNAs in regulating these processes, and discuss recent advances and challenges of implementing epigenetic therapies into clinical practice.

Keywords: epigenetics, EZH2, G9a, long non-coding RNAs, PRC1, PRC2, T cell

BACKGROUND

The immune system comprises a large number of cell types that have the ability to respond to external environmental cues and adopt a wide variety of cell fates. These lineage decisions are critical for the development of proper immune responses to pathogens as well as resolution of inflammatory responses. As part of the adaptive immune system, T cells have the capacity to respond to the external environment by modulating the expression of lineage specific factors which are critical for protecting against a wide variety of pathogens. For the development of distinct T cell lineages, naïve CD4+ T cells must convert the extrinsic instructions provided by encounters with antigen-presenting cells into cell-intrinsic changes (1). These intrinsic changes are largely facilitated by transcription factors that directly induce or repress gene networks and drive T cell differentiation (2). Emerging data demonstrates that lineage specific transcription factors recruit epigenetic complexes to regulate gene expression over multiple rounds of cell division, and their roles are indispensable for maintaining T cell homeostasis.

Deregulation of epigenetic pathways is a feature of many cancers, autoimmune diseases, and neurodegenerative disorders (3–5). The reversible nature of epigenetic modifications makes them attractive targets for pharmacological intervention, and indeed drugs targeting histone-modifying complexes, such as Enhancer of Zeste Homolog 2 (EZH2), are currently being evaluated in patients...
for treatment of malignancy (6) and immune-mediated conditions (7, 8). While recent clinical trials have demonstrated a favorable safety profile of selective inhibition of EZH2 (6), a comprehensive understanding of the role that epigenetic modifying complexes play in the development and function of different immune cell types is relevant to the development and safety of epigenetic therapeutics. Here we review the role of three histone modifying complexes: PRC-1, PRC-2, and G9A in modulating T cell fate decisions. Furthermore, we explore the role of long non-coding RNAs in regulating these processes, and discuss recent advances and challenges associated with implementing epigenetic therapies in clinical practice.

**PRC1, PRC2, G9A, AND LONG NON-CODING RNAs**

**PRC1**
The Polycomb-Group proteins, Polycomb Repressive Complex 1 (PRC1) and 2 (PRC2), mediate post-translational modifications (PTMs) of histones required for cell differentiation and development through the regulation of chromatin structure and gene expression. PRC1 is a multimeric protein complex containing the core proteins RING1A/B, and Polycomb-group ring finger (PCGF) proteins such as Bmi-1 (PCGF4) and Mel-18 (PCGF2). PRC1 functions to mono-ubiquitinate lysine 119 on histone H2A (H2AK119), an epigenetic mark that is associated with transcriptional repression (9). Bmi-1 specifically is highly enriched in pericentric heterochromatin which is required for chromatin compaction and silencing (10). Although Ring1A/B is the catalytic subunit of PRC1, knockdown of Bmi-1 results in a significant loss of H2A ubiquitylation, demonstrating the important role that it plays in facilitating the enzymatic function of PRC1 (11). In the canonical or hierarchical model of Polycomb (PcG)-mediated transcription regulation, PRC1 is primarily described as the maintenance complex which silences target genes previously marked by the initiator complex, PRC2. More recently, a histone-independent role of Bmi-1 in driving NF-κB signaling has been reported (12). An interesting story is also evolving related to a PRC2-independent role for PRC1 in the maintenance of 3D genome structure through association with super-enhancers (13, 14). No immune cell specific data has yet emerged related to these exciting areas of investigation.

**PRC2**
PRC2 modulates chromatin dynamics via the tri-methylation of lysine 27 on histone 3 (H3K27Me3), which is associated with transcriptional repression. EZH2, ubiquitously expressed by many mammalian cell-types, is the enzymatic subunit of PRC2 which contains other supporting non-catalytic proteins namely Suppressor of Zeste (SUZ12), embryonic ectoderm development (EED), Adipocyte Binding Protein 2 (AEBP2) and Retinoblastoma protein Associated protein 46 and 48 (RapA46/48) (15). H3K27me3 recruits protein complexes involved in chromatin compaction and is associated with inactive genes (16). Histone-independent functions of PRC2 have also been reported to play important roles in regulating transcription factor stability and T cell receptor-mediated signaling (17–20). While EZH2 has a role in normal cellular and tissue function, studies involving EZH2 overexpression or genetic mutations show that EZH2 is critical in the development and progression of a variety of cancers (21–29). EZH2 is most frequently associated with the silencing of tumor suppressor genes, and decreased expression of PRC-target genes are associated with poor prognosis (30, 31). Thus, derepression of these genes using selective EZH2 enzymatic inhibitors or disruptors of PRC2 stability are likely to improve clinical outcomes, and are currently being explored in preclinical or clinical studies for cancer therapy (32–38).

**G9a**
The histone methyltransferase G9a and the related G9a-like protein (GLP) form a heterodimeric complex to catalyze mono and di-methylation of lysine 9 on histone 3 (H3K9me1 & H3K9me2) at euchromatin in vivo (39). G9a and GLP are encoded by the EHMT2 and EHMT1 genes, respectively, both of which contain a SET domain necessary for the methylation of lysine residues. G9a has been shown to play a larger role in H3K9me2 methylation in vivo, but levels of H3K9me1 and H3K9me2 are severely reduced in both G9a and GLP knockout models (39). Furthermore, G9a has been shown to promote gene activation through a methyltransferase-independent fashion in different settings, including type II cytokine production in helper T cells, possibly by acting as a scaffold to recruit transcriptional machinery (40, 41). G9a/GLP-mediated H3K9me2 has been associated with cognition and adaptive behavior, germ cell development and meiosis, embryo development, cocaine-induced plasticity, tumor cell growth and metastasis, and more recently the immune response reviewed below (39, 42).

**Long Non-coding RNAs**
Non-coding RNAs have emerged as an exciting new frontier of gene regulation in the immune system. It is now known that 75–90% of the human genome transcriptome is comprised of non-coding RNAs (43, 44). Long non-coding RNAs are defined as transcripts with minimal coding potential that are composed of more than 200 nucleotides; an arbitrary cutoff that distinguishes them from microRNAs (<200 nucleotides). Over 15,000 lncRNA genes have been annotated, although only 159 lncRNAs have known function1-2 (45), highlighting a critical gap in knowledge in the field. They can be classified based on their position relative to protein coding genes as intergenic, intronic and antisense (46). Like mRNAs, long non-coding RNAs undergo transcription by RNA polymerase II, are 5’ capped, spliced and polyadenylated. However, distinct from mRNAs, they lack canonical ORFs (and, therefore have minimal protein-coding potential), tend to be shorter in size, have lower expression levels, fewer exons and can localize to the nucleosome, chromatin or cytoplasm. For example, long intergenic non-coding RNAs localize primarily in the nucleus, in contrast to

---

1. GENCODE, v27 Release. Available online at: https://www.gencodegenes.org/human/release_27.html
2. Long Non-coding RNA Database v2.0 (lncRNAdb). Available online at: http://www.lncrnadb.org/
mRNAs which are primarily localized in the cytoplasm where they undergo translation (47). Furthermore, IncRNAs function by interacting with DNA, RNA, or proteins and the majority modulate transcription in cis (affecting nearby genes), although they can also modulate in trans (targeting distant genes), acting as scaffolds, molecular decoys and guides for epigenetic modifying complexes. Interestingly, IncRNAs can both activate and suppress target genes by a variety of mechanisms and are expressed in a cell-type and stage-specific manner (48, 49). They have been shown to play key roles in autoimmunity, cancer and infection (50–52). A recent comprehensive transcriptomic profiling of T cells demonstrated unique IncRNA signatures for specific T cell phenotypes signifying the relevance of IncRNA to cell and stage specific function (49). Thus, IncRNAs may represent exciting precise therapeutic targets.

**PRC1, PRC2, G9A, AND LNCRNAS IN THE ADAPTIVE IMMUNE SYSTEM**

The development of T cells, an integral component of the adaptive immune system, occurs in the thymus where thymocytes mature into distinct T cell lineages defined by either CD4 or CD8 co-receptor expression. CD4+ T cells and CD8+ T cells are known to possess conventional alpha beta (αβ) T cell receptors (TCR), which recognize antigen-derived peptides bound by major histocompatibility complex (MHC) class II or I molecules, respectively. Upon antigen recognition and inflammatory environmental cues, naïve CD4+ T cells differentiate into distinct effector T helper (Th) subsets by expressing lineage-specific transcriptional programs. Th1, Th2, and Th17 cells mediate protective anti-pathogenic responses against bacteria and viruses via the secretion of distinct IFN-γ, IL-4, and IL-17 effector cytokines, respectively (53). Post-infection, Tregs, a regulatory component of the immune system, are recruited to inhibit effector T cell functions and reestablish homeostasis. Tregs can be generated from the thymus (natural Tregs) or induced in the periphery (iTreg) or in vitro (iTreg) from naïve CD4+ T cells via a FOXP3-driven transcriptome (54–56). Nonetheless, persistent activation of these effector T cell subsets has been associated with the pathogenesis of autoimmune disorders such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and psoriasis (57).

PRC1, PRC2, G9a, and a variety of IncRNAs influence T helper cell differentiation and maintenance by epigenetically regulating transcriptional programs associated with different T cell subsets. Given their significant influence in the pathogenicity of diseases as stated above, we focus here on the role of these molecules in the differentiation and maintenance of Th1, Th2, Treg, and Th17 phenotypes (Figure 1, Table 1).

**Treg/Th17**

Treg and Th17 cells appear to share precursor lineage as demonstrated by in vitro study and murine lineage tracing experiments (77, 78). While TGFβ signaling is required for both effector cell types, IL-6 appears principally responsible for ultimate derivation of Th17 cells (79–81). Ultimately, lineage-specific transcription factors (FOXP3 and RORγt) drive the Treg or Th17 transcriptional program, respectively. FOXP3 and RORγt are known to reciprocally regulate one another, and the delicate balance between suppressive Tregs and effector Th17 cells has proven critical for maintaining immune homeostasis (78). Epigenetic modifying complexes, namely PRC2 and G9a, play key roles in orchestrating the Treg and Th17 transcriptional programs, and disruption of these epigenetic networks are characterized by the development of autoimmunity in murine models of human disease and human inflammatory bowel disease (66, 82, 83).

We and others have demonstrated that mice lacking EZH2 in natural FOXP3+ Tregs developed spontaneous multi-organ inflammation and were more susceptible to experimental models of autoimmunity (65, 66). In addition to decreased frequency of EZH2-depleted Tregs observed in certain murine tissues, DuPage et al. showed that EZH2 was required to promote the FOXP3-mediated gene repression program upon TCR activation as a number of FOXP3-bound genes were de-repressed in the absence of EZH2 (65). In support of the failure of EZH2-deleted Tregs to maintain the expression of Treg-specific signature genes, EZH2-depleted Tregs displayed impaired suppression of effector T cells in vitro (65, 66). Translating these findings from mice to human relevance, Crohn’s disease (CD)-lamina propria CD4+ T cells were transcriptionally different from healthy controls (66). Specifically, normally repressed FOXP3-target genes were upregulated in CD CD4+ T cells and approximately 50% of these differentially expressed genes (DEGs) were EZH2 targets. Moreover, CD4+ T cells displayed a Th1/Th17 effector-like phenotype in contrast to that of healthy controls. Thus, loss of EZH2 function and consequently Treg dysfunction may drive pathophysiological mechanisms of particular autoimmune disorders.

In G9a deficient CD4+ T cells stimulated under Treg or Th17 promoting conditions, a significant increase in FOXP3-expressing and IL-17A-expressing cells is observed. In undifferentiated T cells, G9a normally functions as a mediator of H3K9me2 on loci associated with driving Treg and Th17 phenotypes (42). Loss of G9a-mediated H3K9me2 increases chromatin accessibility to transactivating factors and increases responsiveness to TGFβ (42). Much more work is required to define the molecular underpinnings of G9a’s effects on Treg development, but some consistency is emerging regarding Th17 biology. G9a was shown to be recruited by RelB, a non-canonical NF-κB family member, to silence the IL17A locus and prevent Th17-mediated autoimmunity in an in vivo model of experimental autoimmune encephalomyelitis (EAE) (67). This work is consistent with effects seen in other T cell subsets, namely Th2 cells, in which loss of G9a leads to abnormal IL-17 expression (42). How these effects influence the balance between Treg and Th17 phenotypes is yet to be determined. Thus, G9a may become a viable target for therapeutic intervention of human Th17 mediated diseases.

Three lncRNAs (Flicr, Lnc-Smad-3, and LncEGFR) have been shown to influence Treg function. Flicr is selectively expressed in both human and mouse T regulatory cells and negatively
regulates FOXP3 in cis leading to decreased Treg function and heightened autoimmunity (74). Mechanistically, Flicr modifies chromatin accessibility in the FOXP3 locus, specifically non-coding sequence 3 (CNS3) and accessible region 5 (AR5), leading to decreased expression of FOXP3. In vivo, knockdown of Flicr decreased the incidence of autoimmune diabetes in mice (74).

Lnc-Smad-3 was recently shown to modulate TGFβ-mediated Treg polarization both in human and murine assays (75). Mechanistically, Lnc-Smad3 prevents the histone deacetylase HDAC1 to bind to the SMAD3 promoter region, which renders the chromatin compact and inaccessible to Ash1l, an H3K4 methyltransferase that promotes SMAD3 activation and transcription. From a disease relevance standpoint, these results suggest a potential role for this long non-coding RNA in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (75).

Lnc-EGFR was shown to stimulate Treg differentiation by a forward-feedback loop (51). Mechanistically, Inc-EGFR binds to EGFR using its R1 domain, preventing interaction with c-CBL and ubiquitination. In turn, EGFR activates ERK1/2 and AP-1, which then leads to increased expression of Inc-EGFR and FOXP3, perpetuating increased Treg differentiation. The authors found this to be a critical pathway for hepatocellular carcinoma (51).

LncRNA-1700040D17Rik was found to be deregulated in CD4+ cells derived from a mouse model of autoimmune encephalitis and have been shown to play a role in differentiation of Th17 cells. In vitro, overexpression of LncRNA-1700040D1Rik decreased expression of RORγt and IL-17 in Th17 cells, although the precise mechanism is yet to be known (76). These findings suggest a potential role for this long non-coding RNA in the pathogenesis of multiple sclerosis.

Th1/Th2

Studies investigating the impact of G9a on Th1 biology have shown that the absence of G9a has little effect on Th1 responses in vitro or in vivo, however, it is a critical component of the Th2 regulatory machinery (40). Lehnertz et al. demonstrated G9a to be necessary for expression of lineage-specific Th2-associated cytokines such as IL-4, and that loss of G9a in CD4+ T cells prevents Th2 cell differentiation. Mice with targeted CD4+ T cell deletions of G9a were susceptible to helminth infection by *Trichuris muris* due to the inability to express Th2-associated cytokines. Consistent with previous work (42), the absence of G9a in CD4+ T cells also resulted in the upregulation of IL-17A in vivo. Interestingly, whereas repression of IL-17A appears to be associated with G9a methyltransferase activity (42), Th2 gene regulation by G9a is independent of enzymatic activity, and thought to be related to G9a functioning as a scaffolding protein (40, 41).

The role of PRC1 in regulating T cell lineage fate decisions is best illustrated by the influence it has on the Th1/Th2 axis of development. Both Bmi1 (PCGF 4) and Mel-18 (PCGF 2) have been shown to physically interact with GATA3, a lineage specific transcription factor for Th2 differentiation, in a Ring finger dependent manner (59, 60). Mel-18 has been shown to...
TABLE 1 | Roles of PRC1, PRC2, G9a, and annotated lncRNAs in the development and function of Th1, Th2, Treg, and Th17 cells.

| Role | Gene/Regulator | Function | Th1 | Th2 | Treg | Th17 |
|------|---------------|----------|-----|-----|------|------|
| PRC1 | Absence of Bmi1 impacts Th1 generation and maintenance (58). | Regulates Th2 differentiation and cytokine expression (59, 60). Overexpression of Bmi-1 increases GATA3 expression and stability (59). Loss of Mel-18 impacts Th2 differentiation in vivo (63). | Regulates Th2 differentiation and cytokine expression (59, 60). | Maintains Treg signature gene expression (61). Inactivation leads to systemic immune mediated disease (61). | Knockdown of Mel-18 leads to decreased expression of IL17A, IL17F, and RORC (62). |
| PRC2 | Inhibits Th1 differentiation and cytokine production (63, 64). EZH2 deficiency enhances production of Th1 cytokines and increased T-bet expression (63, 64). | Inhibits Th2 differentiation and cytokine production (63, 64). EZH2 deficiency enhances production of Th2 cytokines and increased GATA3 expression (63, 64). | EZH2 is required to promote the FOXP3-mediated gene repression program following TCR stimulation (65). Loss of EZH2 in Tregs in vivo leads to multi-organ inflammation and increases susceptibility to experimental models of autoimmunity (65, 66). | EZH2-deficient naive CD4+ T cells stimulated under Th17 polarizing conditions displayed enhanced production of IL-17 (63). |
| G9a | No evidence supports a role for G9a in Th1 biology. | Required for Th2-specific cytokine expression (40). Loss of G9a prevents Th2 differentiation and increases IL-17A expression (40, 42). | Absence of G9a in CD4+ T cells is associated with increased FOXP3 expression (42). G9a expression in CD4+ T cells is necessary for development of colitis in mice (42). | Absence of G9a in CD4+ T cells is associated with increased IL-17A expression in vivo and in vitro (42). Recruited by RelB to silence IL17A locus in mouse model of EAE (67). |
| lncRNA | Lnc-MAF-4 promotes Th1 differentiation through silencing of Th2 transcription factor MAF (49, 68). IFNG-AS1 recruits H3-K4-methyltransferase to Ifng locus and is upregulated in response to Th1-polarizing cytokines (52, 69-71). | Th2-LCR-lncRNA recruits WDR5-containing complexes to Th2-specific cytokine loci facilitating their expression (72). LincR-CcR2-B′ AS interacts with GATA-3 to upregulate chemokine genes necessary for Th2 migration (73). | Flic negatively regulates FOXP3 leading to decreased Treg function (74). Lnc-Smad-3 regulates TGFβ mediated Treg differentiation by interacting with HDAC1 (75). Lnc-EGFR promotes Treg differentiation through interactions with EGFR (51). | Overexpression of LncRNA-1700040D17Rik was associated with decreased expression of RORγt and IL-17 in Th17 cells (76). |

regulate GATA3 transcription, and knockout of mel-18 severely impacts Th2 differentiation in vivo (60). Bmi-1 regulates Th2 cell differentiation by acting as an inhibitor of GATA3 degradation and regulator of its stability. Bmi-1 overexpression in itself leads to an increase in GATA3 expression and an increase in Th2 cell differentiation under a Th2 specific cytokine milieu. Comparatively little data exist regarding the role of PRC1 in Th1 cell development/function; however adoptive transfer of CD4+ T cells from Bmi1−/− mice into nude mice showed impaired generation and maintenance of memory Th1 cells through Bmi1-mediated repression of Noxa, a pro-apoptotic gene (58).

The role of EZH2 in modulating effector T function was recently illuminated by Yang et al. who showed that EZH2-deficient naïve CD4+ T cells stimulated under Th1, Th2 or Th17 polarizing conditions displayed enhanced production of IFN-γ, IL-13 or IL-17 cytokines, respectively (63). Moreover, Tumees et al. also showed that EZH2 deficiency in naïve CD4+ T cells led to the upregulation of Th1 and Th2-associated cytokines with concomitant increase in lineage-specific transcription factors T-bet and Gata3, respectively (64). However, in vivo studies have revealed that EZH2 plays a dichotomous role in the differentiation and senescence of CD4+ T cells (63). For example, in an in vivo model of Listeria monocytogenes infection known to induce a Th1 response, CD4+ T-specific EZH2 deleted mice displayed impaired clearance of infection due to decreased survival of memory Th1 cells (84). Additionally, OVA-specific EZH2-deficient Th2 cells were pathogenic in a mouse model of allergic asthma due to an accumulated and exaggerated immune response from memory Th2 cells (64). Taken together, EZH2 inhibits effector cytokine production in naïve CD4+ T cells, and loss of EZH2 enhances differentiation to effector Th cells as well as effector Th cell plasticity. Based on evidence from in vivo studies in mice in the context of EZH2 deletion in T cells, effector Th cell dysfunction is consistent across all disease models, evidently through impaired clearance of pathogens or aggravated autoimmunity (potentiated tissue destruction). Additionally, H3K27me3-independent functions of EZH2 have been reported in T cells expressing conventional αβ TCRs (17, 18). Varanakumar et al. demonstrated that EZH2 prevents NKT cell expansion through methylation, ubiquitination and subsequent degradation of the transcription factor promyelocytic leukemia zinc finger (PLZF) (17). In vivo studies have demonstrated that an increase in the frequency of NKT cells in the thymus and spleen occurs as a result of CD4+ T-specific EZH2 deletion, which may contribute to the perturbed immunity seen in murine studies previously mentioned (63, 64, 84).

Two lncRNAs, MAF-4, and IFNG-AS1 (also called NeST or Tmevpg1), have been shown to influence Th1 biology by...
recruiting different epigenetic modifying complexes. Linc-MAF-4 is selectively expressed in Th1 cells and promotes Th1 differentiation through epigenetic silencing of the Th2 transcription factor MAF. Downregulation of linc-MAF-4 in human CD4+ cells skewed differentiation toward a Th2 phenotype. Mechanistically, linc-MAF-4 promotes a cis chromatin looping conformation, leading to the recruitment of chromatin remodelers EZH2 and LSD1 that place repressive H3K27me3 marks on the promoter region of MAF-4 silencing its expression (49). Recently, linc-MAF-4 was shown to be involved in the pathogenesis of multiple sclerosis by promoting Th1 cell differentiation (68). Thus, far, linc-MAF-4 has not been studied in vivo.

IFNG-AS1 is expressed in CD4+ Th1, CD8+, and natural killer cells (52, 69). It is upregulated in CD4+ cells in response to Th1-differentiating cytokine stimuli and plays a critical role in transcription of Ifng. This has been demonstrated both in vitro and in vivo. Mechanistically, it has been shown to recruit the H3K4-methyltransferase complex to the Ifng locus, leading to placement of activating marks at the promoter region. It has been associated with the pathogenesis of Hashimoto’s thyroiditis (70), ulcerative colitis (71), and the immune response to viral infections in vivo (52).

Two IncRNAs, Th2-LCR-IncRNA and lincR-Ccr2-5’AS, have been shown to influence the development and function of Th2 cells. Th2-LCR-IncRNA is selectively expressed in human Th2 cells and is transcribed in the RAD50 locus and epigenetically regulates expression of IL-4, IL-5 and IL-13 (72). Mechanistically, Th2-LCR-IncRNA recruits WDR5-containing complexes to targeted cytokine loci, enhancing transcription. Knockdown of human Th2-LCR-IncRNA in vitro causes major loss of expression of IL-4, IL-5 and IL-13 in Th2 cells through loss of H3K4me3 activating marks (72). Unfortunately, Th2-LCR-IncRNA is not conserved in mice, complicating in vivo studies.

LincR-Ccr2-5’AS is selectively expressed in mouse Th2 cells and upregulates CCR1, CCR2, CCR3 and CCR5 chemokine genes in a GATA3-dependent fashion (73). Interestingly, knockdown of this lincRNA not only affected neighboring genes CCR2 and CCR3, but also affected nearly 1,200 genes some of which were located in distant loci, suggesting it can act in both cis and trans. Although the precise mechanism is yet to be fully understood, in vitro knock down of lincR-CcR2-5’AS did not result in chromatin accessibility or modification of H3K4me3, suggesting that it does not act through recruitment of histone-modifying enzymes or chromatin structure modifications.

**FUTURE PERSPECTIVES: EPGENETIC MODULATION OF T CELLS IN CLINICAL PRACTICE**

Epigenetic mechanisms of disease are in theory inducible and reversible through environmental manipulation, however, some epigenetic features have been shown to be maintained after cellular division as a result of self-enforcing feedback mechanisms (85). The heritable, yet reversible nature of epigenetic therapy makes this a promising option for treatment. Persistence of epigenetic maintenance of engineered modifications has been shown to be stable up to 40 days post modification induction in vivo (86). Most epigenetic drugs currently in use inhibit DNA methyltransferase and histone deacetylase activity, and have been shown to reverse immune suppression and thus sensitize the host immune system in combination with anti-cancer therapies. Several anti-cancer mechanisms have been reported, such as enhancing antigen processing and presenting machinery pathways, inhibiting immune checkpoints, and enhancing chemokine production. For patients, there are three treatment options available: therapies reported to affect DNA methylation, inhibitors of histone post-translational modifications, and compounds interfering with non-coding RNA regulation (87). Repurposing drugs and screening for new compounds that display converse effects to treatment autoimmune disease is an exciting new option for autoimmune illnesses.

Distinct DNA methylation profiles have been demonstrated in CD8+ and CD4+ T cells isolated from patients experiencing autoimmune diseases (88–90). Epigenetic based therapeutics currently being employed for the clinic for non-inflammatory conditions, such as arrhythmias (procainamide), hypertension (hydralazine), and neoplasia (5-azacytidine), have been shown to induce auto-reactive pathology (7, 8). However, the 5-azacytidine derivative 5-aza-2’dexoyctydine, which is also a DNA methyltransferase inhibitor used in hematological malignancies, has been shown to have a positive outcome when administered in animal models of diabetes (91), colitis (92), multiple sclerosis (93), and graft-versus-host disease (GvHD) (94). We need a better understanding of the implications of DNA methylation, the pharmokinetics of available compounds, and synergistic effects of combination therapy with immunomodulatory drugs already in practice for autoimmune diseases to allow us to develop and implement novel therapies. As of now, we are lacking a therapeutic arsenal to target global hypomethylation, which is most often associated with lymphocytes recovered from patients experiencing some of the most common autoimmune diseases.

The ubiquitous expression of EZH2 and the opposing role it plays in different cell-types makes EZH2 a delicate therapeutic target. Recent identification of PRC2- and H3K27me3-independent EZH2 functions in oncogenesis indicates that a complete suppression of all oncogenic functions of EZH2 is required to combat cancer. Anti-EZH2 therapy inhibits methylation at key repression/silencing associated histone marks, and these compounds have emerged as a promising therapy for cancer treatment, especially for B cell non-Hodgkin’s lymphoma. However, we have observed that systemic anti-EZH2 therapy leads to mucosal hypersensitivity in mice. One complicating factor is that EZH2 is also utilized by PRC1 in the nucleus, therefore more study needs to be undertaken to dissect the specific roles these complexes play in inflammation before on can determine whether histone methyltransferase inhibitors can be co-opted for anti-inflammatory therapy. Of note, cytosolic forms of PRC2 have been shown in murine models to be necessary for TCR-mediated activation of signaling pathways that drive T cell proliferation and autoimmunity. Thus,
that promotes gene silencing through recruitment of PRC2 caused by excessive T cell activation (98, 99). One option being pursued in cancer therapies is to directly target HOTAIR; a primarily trans-acting long-non coding RNA that promotes gene silencing through recruitment of PRC2 and LSD1 complexes, resulting in trimethylation of H3K27 and demethylation of H3K4, respectively (100–102). Knocking down HOTAIR provides compelling evidence for therapeutic targeting in cancer. Arresting glioblastoma multiform cell migration and invasion through this approach is a case in point (103). To overcome the limitation of genetic targeting, peptide nucleic acids have been developed which disrupt complex function. This approach has had positive results in inhibiting NF-κB activity in addition to decreasing ovarian and breast cancer properties such as reduced tumor formation and survival (104). The potential for this approach in inflammatory diseases is still to be determined.

Precision medicine has brought about the advent of using CRISPR/Cas9 to target this gene editing tool to target epigenetic modifying enzymes to precise locus specific locations on the genome instead of the DNA endonucleases the technology originally utilized (105). This technique can be exploited to recruit enzymes that impact the methylation of the DNA, enzymes that post-translationally modify the histones, and proteins which interfere with non-coding RNA regulation. Further, it has been recently reported CRISPR/Cas9 technology can be rapidly delivered via a non-viral delivery technique capable of integrating large DNA sequences (106). These new developments will allow us flexible and precise epigenetic manipulation toward creating therapeutically epi-engineered primary human immune cells without the off-target effects associated with systemic epigenetic therapies.

**AUTHOR CONTRIBUTIONS**

WF contributed conception and design of the manuscript. JG, MB, GR, AB, MG, MS, and OS wrote sections of the manuscript. JG wrote the first draft of the manuscript. All authors provided critical revision and final approval of the manuscript.

**FUNDING**

Supported by grants 5R01AI089714-08, 5R01AI089714-08S1, 30DK084567, and CCFA #401661.

**REFERENCES**

1. Wilson CB, Rowell E, Sekimoto M. Epigenetic control of T-helper-cell differentiation. *Nat Rev Immunol*. (2009) 9:91–105. doi: 10.1038/
nri2487

2. Kanno Y, Vahedi G, Hirahara K, Singleton K, O’Shea JJ. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. *Annu Rev Immunol*. (2012) 30:707–
31. doi: 10.1146/annurev-immunol-020711-075658

3. Urdinguio RG, Sanchez-Mut Jv, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. *Lancet Neurol*. (2009) 8:1056–72. doi: 10.1016/S1474-4422(09)70262-5

4. Esteller M. Cancer epigenomics: DNA methyleomes and histone-modification maps. *Nat Rev Genet*. (2007) 8:286–98. doi: 10.1038/nrg2005

5. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martín-Subero JI, Rodriguez-Urbela J, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. *Genome Res*. (2010) 20:170–9. doi: 10.1101/gr.100289.109

6. Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-
in-human, open-label, phase 1 study. *Lancet Oncol*. (2018) 19:649–59. doi: 10.1016/S1474-4247(18)30145-I

7. Quddus J, Johnson KJ, Gavalchik J, Amento EP, Chrisp CE, Yung RL, et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. *J Clin Invest*. (1993) 92:58–53. doi: 10.1172/jci116376

8. Deng C, Lu Q, Zhang Z, Rao T, Atwood J, Yung R, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. *Arthritis Rheum*. (2003) 48:746–56. doi: 10.1002/art.10833

9. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in Polycomb silencing. *Nature* (2004) 431:873–8. doi: 10.1038/nature02985

10. Abdouh M, Hanna R, El Hajar J, Flami A, Bernier N. The polycomb repressive complex 1 protein BMI1 is required for constitutive heterochromatin formation and silencing in mammalian somatic cells. *J Biol Chem*. (2016) 291:182–97. doi: 10.1074/jbc.M115.662403

11. Tavares L, Dimitrova E, Osley D, Webster J, Poot R, Demmers J, et al. RYBP-PRC1 complexes mediate H2A ubiquitination at polycomb target sites independently of PRC2 and H3K27me3. *Cell* (2012) 148:664–78. doi: 10.1016/j.cell.2011.12.029

12. Okuyama Y, Tanaka Y, Jiang JJ, Kamiyama D, Wasmuth M, Ota M, et al. Bmi1 regulates Ilkappa/alpha Degradation via Association with the SCF Complex. *J Immunol*. (2018) 201:2264–72. doi: 10.4021/jimmunol.1701223

13. King HW, Furova NA, Blackledge NP, Vose RJ. Polycomb repressive complex 1 shapes the nucleosome landscape but not accessibility at target genes. *Genome Res*. (2018) 28:1494–150. doi: 10.1101/gr.237180.118

14. Chan HL, Beckedorff F, Zhang Y, Garcia-Huidobro J, Jiang H, Colaprico A, et al. Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms. *Nat Commun*. (2018) 9:3377. doi: 10.1038/s41467-018-05728-x

15. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. *Nature* (2011) 469:343–9. doi: 10.1038/nature09784

16. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. *Nat Rev Genet*. (2007) 8:263–9. doi: 10.1038/nrg2046

17. Vasanthakumar A, Xu D, Liu AT, Ianarella MC, van Gisbergen KP, Poot R, et al. Regulation of the positive transcriptional effect of PLZF through a non-canonical function of Ezh2 preserves immune homeostasis. *Nat Commun*. (2018) 9:3810. doi: 10.1038/s41467-018-05728-x

18. Koubi M, González de la Rosa M, Pan E, Hwang ES, Jao C, Lasky G, et al. Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity. *Nucleic Acids Res*. (2018) 46:3339–50. doi: 10.1093/nar/gky080
19. Dobenecker MW, Park JS, Marcello J, McCabe MT, Gregory R, Knight SD, et al. Signaling function of PRC2 is essential for TCR-driven T cell responses. J Exp Med. (2018) 215:1101–13. doi: 10.1084/jem.20170084

20. Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, Marqu eron R, et al. Polycrom group protein ezH2 controls actin polymerization and cell signaling. Cell (2008) 132:425–36. doi: 10.1016/j.cell.2005.02.029

21. Velechutina I, Shakhnovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. (2010) 116:5247–55. doi: 10.1182/blood-2010-04-280149

22. Varambally S, Dhakasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycrom group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419:624–9. doi: 10.1038/nature01075

23. Bracken AP, Pasini D, Capra M, Prosperi ne E, Colli E, Helin K. EZH2 is downstream of the p53-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. (2003) 22:5323–35. doi: 10.1093/emboj/cdg542

24. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas T, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. (2006) 24:2678–73. doi: 10.1200/JCO.2005.01.3180

25. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. (2010) 42:181–5. doi: 10.1038/ng.518

26. Bodor C, O’Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H, et al. A selective inhibitor of EZH2 blocks H3K27 methylation by inhibition of methyltransferase EZH2. Durable tumor regression in genetically altered malignant rhabdoid tumors and kills mutant lymphoma cells. Nat Chem Biol. (2011) 2:1034–1037. doi: 10.1038/nchembio.480

27. Sneeringer CJ, Scott MP, Kunz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA. (2010) 107:20890–5. doi: 10.1073/pnas.1012525107

28. Vap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Tyr641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. (2011) 117:2451–9. doi: 10.1182/blood-2010-11-321208

29. Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. (2016) 22:128–34. doi: 10.1038/nm.4036

30. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. (2008) 647:21–9. doi: 10.1016/j.mrmm.2008.07.010

31. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, et al. A polycrom repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. (2007) 67:10657–63. doi: 10.1158/0008-5472.CAN-07-2498

32. Knutson SK, Wigle TJ, Warholic NM, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. (2012) 8:890–6. doi: 10.1038/nchembio.1084

33. Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, et al. Identification of potent, selective, cell-active inhibitors of the histone tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. (2010) 107:20890–5. doi: 10.1073/pnas.1012525107

34. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Proc Natl Acad Sci USA. (2010) 107:20890–5. doi: 10.1073/pnas.1012525107

35. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. (2014) 13:842–54. doi: 10.1158/1355-7163.MCT-13-0773

36. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. (2014) 13:842–54. doi: 10.1158/1355-7163.MCT-13-0773

37. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. (2014) 13:842–54. doi: 10.1158/1355-7163.MCT-13-0773

38. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. (2013) 9:643–50. doi: 10.1038/nchembio.1331

39. Shinkai Y, Tachibana M, H3K9 methyltransferase G9a and the related molecule G3BP, Genes Dev. (2011) 25:781–8. doi: 10.1101/gad.2027411

40. Lehner B, Northrop JF, Antignano F, Burrows K, Hadii S, Mullaly SA, et al. Activating and inhibitory functions for the histone lysine methyltransferase G9a in T helper cell differentiation and function. J Exp Med. (2010) 207:915–22. doi: 10.1084/jem.20100363

41. Scheer S, Zaph C. The lysine methyltransferase G9a in immune cell differentiation and function. Front Immunol. (2017) 8:249. doi: 10.3389/fimmu.2017.00249

42. Antignano F, Burrows K, Hughes MR, Han JM, Kron KJ, Penrod NM, et al. Methyltransferase G9a regulates T cell differentiation during murine intestinal inflammation. J Clin Invest. (2014) 124:1945–55. doi: 10.1111/jc.12199

43. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, tilted H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. (2012) 22:1775–89. doi: 10.1101/gr.132159.111

44. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekmans H, Kokocinski F, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. (2012) 22:1760–74. doi: 10.1101/gr.135350.111

45.根本没有

46.根本没有

47.根本没有

48.根本没有

49.根本没有

50.根本没有

51.根本没有

52.根本没有

53.根本没有

54.根本没有

55.根本没有

56.根本没有

57.根本没有

58.根本没有

59.根本没有
58. Yamashita M, Kuwahara M, Suzuki A, Hirakara K, Shinnakus R, Hosokawa H, et al. Bmi1 regulates memory CD4T cell survival via repression of the Noxa gene. J Exp Med. (2008) 205:1109–20. doi: 10.1084/jem.20072000
59. Hosokawa H, Kimura MY, Shinnakus R, Suzuki A, Miki T, Koseki H, et al. Regulation of Th2 cell development by Polycomb group gene bmi-1 through the stabilization of GATA3. J Immunol. (2006) 177:7636–64. doi: 10.4049/jimmunol.177.11.7656
60. Kimura M, Koseki Y, Yamashita M, Watanabe N, Shimizu C, Katsumoto T, et al. Regulation of Th2 cell differentiation by mel-18, a mammalian polycomb group gene. Immunity (2001) 15:275–87. doi: 10.1016/S1074-7613(01)00182-0
61. Gonzalez M, Sagstetter M, Svingen P, Bamidele AO, Sarmento OF, Sun Z, et al. The epigenetic complex PRC-1 maintains T regulatory cell lineage instability. AGA Abstracts (2017) 152:579.
doi: 10.5864/15005873(2017)30612-1
62. Hod-Dvorai R, Jacob E, Boyko Y, Avni O. The binding activity of Imr2-Del1000040D17Rik in Th17 cell differentiation and the pathogenesis of EAE. Immunopharmacol Immunochem (2017) 47:141–9. doi: 10.1016/j.impph.2017.03.014
71. Zhou X, Bailey-Buckrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. (2009) 10:1000–7. doi: 10.1038/ni.1774
72. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, et al. TGF-beta-induced Foxp3 induction of Th1(7) cell differentiation by antagonizing RORgamma function. Nature (2008) 453:236–40. doi: 10.1038/nature06878
73. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. (2003) 198:1875–86. doi: 10.1084/jem.20030152
74. Mangan PR, Harrington LE, OQuinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the Th17 lineage. Nature (2004) 441:231–4. doi: 10.1038/nature04754
75. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. (2007) 8:967–74. doi: 10.1038/nm1488
76. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut (2003) 52:65–70. doi: 10.1136/gut.52.1.65
77. Luo A, Leach ST, Barnes R, Hesson LB, Grimm MC, Simar D. The microbiota and epigenetic regulation of T helper 17/regulatory T cells: in search of a balanced immune system. Front Immunol. (2017) 8:417. doi: 10.3389/fimmu.2017.00417
78. Zhang Y, Kinkel S, Mapkovic S, Bandala-Sanchez E, Tanzer MC, Naselli G, et al. The polycomb repressive complex 2 governs life and death of peripheral T cells. Blood (2014) 124:737–49. doi: 10.1182/blood-2013-12-544106
79. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. (2016) 17:487–500. doi: 10.1038/nrg.2016.59
80. Saudendorf EA, Stepper P, Gomj JH, Hoo L, Morgan A, Allen MD, et al. Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. Nat Commun. (2017) 8:1450. doi: 10.1038/s41467-017-01078-2
81. Jenuwein T, Allis CD. Translating the histone code. Science. (2001) 293:1074–80. doi: 10.1126/science.1063127
82. Maltby VE, Graves MC, Lea RA, Benton MC, Sanders KA, Tajouri L, et al. Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients. Clin Epigenetics (2015) 7:118. doi: 10.1186/s13348-015-0152-7
83. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheumat. (1999) 33:1665–73. doi: 10.1002/1529-0167(199907)33:7<1665::AID-ARTH2.0.CO;2-1>3.0.CO;2-1
84. Zhang Y, Zhao M, Sawalla AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4(+) T cells of systemic lupus erythematosus. J Autoimmun. (2013) 41:92–9. doi: 10.1016/j.jaut.2013.01.005
85. Zheng Q, Xu Y, Liu Y, Zhang B, Li X, Guo F, et al. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice. J Mol Med. (2009) 87:1191–205. doi: 10.1007/s00109-009-0530-8
86. Lal G, Zhang NW, van der Touw DY, Ju W, Rottoning EP, Bromberg JS. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. (2009) 182:259–73. doi: 10.4049/jimmunol.182.1.259
87. Chan MW, Chang CB, Tung CH, Sun J, Suen JL, Wu SF. Low-dose 5-aza-2-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells. Mol Med. (2014) 20:248–56. doi: 10.2119/molmed.2013.00159
88. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C, et al. Immunomodulatory effect of 5-aza-2-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells. Mol Med. (2014) 20:248–56. doi: 10.2119/molmed.2013.00159
89. Tschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, et al. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med. (2015) 7:108. doi: 10.1186/s13073-015-0233-4
96. Serghiou S, Kyriakopoulou A, Ioannidis JP. Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. *Mol Cancer.* (2016) 15:50. doi: 10.1186/s12943-016-0535-1
97. Li Z, Li X, Jiang C, Qian W, Tse G, Chan MTV, et al. Long non-coding RNAs in rheumatoid arthritis. *Cell Prolif.* (2018) 51:1–6. doi: 10.1111/cpr.12404
98. Meng L, Ward AJ, Chan S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. *Nature* (2015) 518:409–12. doi: 10.1038/nature13975
99. Sheikh Mohamed J, Gaughwin PM, Lim B, Robson P, Lipovich L. Conserved long noncoding RNAs transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells. *RNA* (2010) 16:324–37. doi: 10.1261/rna.1441510
100. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, et al. Long noncoding RNA as modular scaffold of histone modification complexes. *Science* (2010) 329:689–93. doi: 10.1126/science.1192002
101. Loewen G, layawickramarajah J, Zhuo Y, Shan B. Functions of IncRNA HOTAIR in lung cancer. *J Hematol Oncol.* (2014) 7:90. doi: 10.1186/s13045-014-0090-4
102. Gao JZ, Li J, Du JL, Li XL. Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence. *Oncol Lett.* (2016) 11:1791–8. doi: 10.3892/ol.2016.4130
103. Zhou X, Ren Y, Zhang J, Zhang C, Zhang K, Han L, et al. HOTAIR is a therapeutic target in glioblastoma. *Oncotarget* (2015) 6:8353–65. doi: 10.18632/oncotarget.3229
104. Ozes AR, Wang Y, Zong X, Fang F, Pilrose J, Nephew KP. Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. *Sci Rep.* (2017) 7:894. doi: 10.1038/s41598-017-00966-3
105. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* (2013) 154:442–51. doi: 10.1016/j.cell.2013.06.044
106. Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. *Nature* (2018) 559:405–9. doi: 10.1038/s41586-018-0326-5

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.